LDS/Medical Tests/Nalbuphine, Urine

Nalbuphine, Urine

Nalbuphine is a synthetic phenanthrene opioid agonist/antagonist, chemically similar to naloxone and oxymorphone. As an agonist, nalbuphine is equipotent with morphine but due to its mixed mode of action, nalbuphine may be useful in minimizing or treating respiratory depression, pruritis or other opioid-related adverse effects. Nalbuphine is therefore used in combination with other opioids for pre- and post-surgical anesthesia. The typical route of administration is by injection: intramuscular, intravenous, and subcutaneous. It is metabolized to nornalbuphine and glucuronide conjugates. The half-life of nalbuphine is 1.9-7.7 hours. The duration of analgesia is 3-6 hours.

Approximately 70% of a typical dose of nalbuphine is eliminated in the urine. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.

Common side effects: CNS depression, sedation, confusion, hostility, delusions, hallucinations, bradycardia, nausea, vomiting, dizziness, clamminess. Can be addictive. Overdose effects include respiratory collapse, cardiac arrest, coma, and possible death.

Nalbuphine and metabolites can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A qualitative positive result indicates only the presence of Nalbuphine and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic Level: 10-100 ng/mL
Toxic level: >200 ng/mL     

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection or laboratory, whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

Many, including Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Thin Layer Chromatography (TLC). Many laboratories include a pre-analytical hydrolysis reaction to liberate the glucuronide conjugates, which may improve detection. Immunoassays for nalbuphine detection are not commercially available.

Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* and *OPRM1* variants could guide drug and dose selection. Patients with poor or rapid metabolizer phenotypes for *CYP2D6* should not receive codeine because of the inherent risk of therapeutic failure or toxicity, respectively. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.